Joan L Robbins

US Patent:

6770633, Aug 3, 2004

Filed:

Oct 25, 2000

Appl. No.:

09/696791

Inventors:

Joan M. Robbins - San Diego CA
Richard Tritz - San Diego CA

Assignee:

Immusol, Inc. - San Diego CA

International Classification:

C07H 2104

US Classification:

514 44, 435 6, 435 913, 536 245, 536 232

Abstract:

As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase.

US Patent:

20040248830, Dec 9, 2004

Filed:

Jun 25, 2004

Appl. No.:

10/478019

Inventors:

Richard Tritz - San Diego CA, US
Benjamin Keily - San Diego CA, US
Cellia Habita - San Diego CA, US
Joan Robbins - San Diego CA, US
Jack Barber - San Diego CA, US

International Classification:

A61K048/00
C07H021/04

US Classification:

514/044000, 536/023100

Abstract:

The present invention provides genes, nucleic acid sequences, proteins and amino acid sequences that are, involved in the inhibition of apoptosis induction in cells. The invention also provides the RNA correlates of these genes and nucleic acid sequences. Further provided are isolated nucleic acid molecules that interact with the genes, nucleic acid sequences and RNA correlates disclosed herein, such that their inhibitory effect on apoptosis induction is lessened and, therefore, apoptosis induction is facilitated.

US Patent:

20050009168, Jan 13, 2005

Filed:

May 11, 2004

Appl. No.:

10/843718

Inventors:

Joan Robbins - San Diego CA, US
Marylou Gibson - Carlsbad CA, US

International Classification:

C12N007/02
C12M001/34

US Classification:

435239000, 435287100

Abstract:

The present invention provides an apparatus for the purification of Adeno-associated virus (AAV) and methods of use including an anion exchange filter unit and a cation exchange capture unit. At one end, the cation exchange capture unit reversibly engages the anion exchange filter unit and when engaged is in fluid communication. The cation exchange capture unit may, at the opposing end, reversibly engage a syringe or apparatus able to provide negative pressure to draw a fluid containing AAV through the anion exchange filter unit then cation exchange capture unit where the AAV is captured. The anion exchange filter unit is disengaged and the purified AAV is eluted from the cation exchange capture unit.

US Patent:

20060178326, Aug 10, 2006

Filed:

Jan 8, 2004

Appl. No.:

10/753718

Inventors:

Joan Robbins - San Diego CA, US
Richard Tritz - San Diego CA, US

International Classification:

A61K 48/00
A61K 38/46

US Classification:

514044000, 424094600

Abstract:

As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase.

US Patent:

20070280944, Dec 6, 2007

Filed:

Apr 1, 2005

Appl. No.:

10/594850

Inventors:

Joan Robbins - San Diego CA, US
Mark Cantwell - San Diego CA, US

Assignee:

Adventrx Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 39/395
A61K 31/525
A61K 31/7072
A61K 31/704
A61K 31/4745
A61K 31/337

US Classification:

424145100, 514251000, 514049000, 514269000, 514109000, 514410000, 514449000, 514283000, 514034000, 514492000

Abstract:

The present invention provides novel uses and compositions for 5,10-methylene tetrahydrofolate (“5,10-CH-THFA”) in the treatment of cancer. The present invention is based on the surprising result that 5,10-CH-THFA, while increasing the efficacy of 5-fluoruracil (5-FU) in reducing the rate of tumor growth and increasing survivorship, also reduces the toxicity to the patient of 5-FU. The present invention provides methods and compositions for treating cancer patients that include 5-FU, 5,10-CH-THFA, and one or more additional anticancer drugs. Such methods and compositions can provide increased efficacy and reduced toxicity when compared with current treatment modalities.

US Patent:

20080045482, Feb 21, 2008

Filed:

Jan 25, 2007

Appl. No.:

11/627062

Inventors:

Joan Robbins - San Diego CA, US
Shani Waninger - Carlsbad CA, US

Assignee:

Adventrx Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 31/66
A61P 31/12

US Classification:

514120000

Abstract:

The present invention provides compositions and methods for inhibiting the replication of influenza virus by administering thiophosphonoformic acid alone or in combination with a neuraminidase inhibitor, for example, oseltamivir.

US Patent:

20090221594, Sep 3, 2009

Filed:

Nov 30, 2006

Appl. No.:

12/095458

Inventors:

Andrew X. Chen - San Diego CA, US
Hongjie Wu - San Diego CA, US
Mark J. Cantwell - San Diego CA, US
Joan M. Robbins - San Diego CA, US

International Classification:

A61K 31/4985

US Classification:

514249

Abstract:

The invention provides a stable lyophilized composition of 5,10 methylenetetrahydrofolate suitable for use in the treatment of cancer and other therapies. The composition comprises 5,10-MTHF in combination with citric acid and ascorbic acid, with the ratio of citric acid to ascorbic acid from about 0.75:1 to about 2.25:1 by weight, and the ratio of total citric acid and ascorbic acid to 5,10-MTHF from about 1.4:1 to about 3.4:1 by weight. Prior to lyophilization, the solution is adjusted to an essentially neutral pH.

US Patent:

20130130986, May 23, 2013

Filed:

Mar 29, 2011

Appl. No.:

13/638490

Inventors:

Harry E. Gruber - Rancho Santa Fe CA, US
Douglas J. Jolly - Encinitas CA, US
Omar Perez - San Diego CA, US
Derek G. Ostertag - San Diego CA, US
Joan M. Robbins - San Diego CA, US

Assignee:

TOCAGEN INC. - San Diego CA

International Classification:

A61K 48/00
A61K 38/22

US Classification:

514 129

Abstract:

This disclosure provides modified cytosine deaminases(CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders. It further provides use of such modified CDs with a thymosin-alpha-1 polypeptide in the treatment of disease and disorders.